Basic self-disorders may play a role in the development of depression in schizophrenia: a seven-year follow-up study.

Introduction: Depression is the most common co-morbid psychiatric disorder in patients with schizophrenia and has a negative effect on functional outcomes and quality of life. There are several possible pathways leading to depressive symptoms in schizophrenia. Self-disorders are disturbances in the deepest, pre-reflective level of the self and are suggested to be core features of schizophrenia.

The 2025 Motile Active Matter Roadmap.

Activity and autonomous motion are fundamental aspects of many living and engineering systems. Here, the scale of biological agents covers a wide range, from nanomotors, cytoskeleton, and cells, to insects, fish, birds, and people. Inspired by biological active systems, various types of autonomous synthetic nano- and micromachines have been designed, which provide the basis for multifunctional, highly responsive, intelligent active materials.

Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors.

Purpose: BMS-986299 is a first-in-class, NOD-, LRR-, and pyrin-domain containing-3 (NLRP3) inflammasome agonist enhancing adaptive immune and T-cell memory responses.

Materials And Methods: This was a phase-I (NCT03444753) study that assessed the safety and tolerability of intra-tumoral BMS-986299 monotherapy (part 1A) and in combination (part 1B) with nivolumab, and ipilimumab in advanced solid tumors. Reported here are single-center results.